where he came under the influence of Pelletier and others who were working on quinine products, he began to cultivate a reputation for processing quinine for the English market. Similarly, Allen and Hanbury began a company practice of processing oils as part of their efforts to supply their market with some lines that were less well served previously. 4 As pharmaceutical firms grew from apothecary shops to family companies and then to large corporations, their relation with the medical community also changed. Pharmacists held a tenuous place in the medical world of the nineteenth century, although they provided important services to those members of the public who did not use doctors and supplied those who did with medicines. Towards the end of the century drug makers distanced themselves from pharmacists and their informal practice of medicine. As the distinction grew between reputable manufacturers who sought the professional market-"ethical" pharmaceutical producers-and the popular "patent medicine" makers, the large companies looked for a compromise between the two. They hoped to establish reputations for quality but also to reap The basis of this faith was a coherent system of therapeutic theory. Beneath it lay the notion that the body was in constant dynamic relation with its environment. Equilibrium was associated with health, imbalance with disease, and the purpose oftherapeutics was to restore order. Humoral theory and localistic models of disease were reconciled by the principle that every part of the body was related inextricably to every other. The early nineteenth century conception of the body was as a system of intake and outgo. Doctors and patients could see and judge excretions or appetite; they therefore seemed an obvious monitor of health. Treatment, as a result, concentrated on diet and excretion, and perspiration and ventilation, as the aspects that could be controlled to produce a stable system. If a person had a wound, for example, he or she might be treated with a salve locally, but the holistic implications for the body might well necessitate the administration of a stimulant in addition.
Enormous quantities of medicines were consumed in order to maintain or re-establish health. Special drugs were also administered in life crises or at changes of the season, when a patient's body was more liable to lose its healthy equilibrium. Cathartics, for example, were given in the spring and autumn to help the body adjust to these cyclical changes. Mercury treatments and bleeding were the most common severe treatments, both producing dramatic effects.
This business terms, reasonably stable but unable to supply the domestic market with many of the products that had so changed the industry abroad. There were no major industrial laboratories for product development, and British manufacturers, who had been complimented at numerous trade exhibitions for the quality oftheir standard products, seemed incapable of doing much else. This inability was recognised and much commented on, but little changed. During the first world war the firms continued to get shipments from Continental suppliers while publicly resolving to rectify their inadequacies. Major contracts to supply the armed forces had to be given to American companies, and The German example
The United States, Switzerland, and Germany had long had vague and unenforceable rules guarding against the sale of harmful agents. In Britain the sale of poisons was controlled and laws intending to curb opium abuse were tried at various times. But it was not all that clear in Britain whether selling a medicine that differed substantially from its description in the British Pharmacopoeia was illegal. In various test cases pharmacists were able to argue either that the customer had not specified that medicine exactly, or that the Pharmacopoeia did not have what was wanted, or that its description was inadequate. This vagueness prevailed in Germany also; and in the American states legislation varied widely, but all had weak provisions for enforcement.' 2 From the point of view of the-British industry especially the arrangements that the firms entered into became a major aspect of their business. Regarded as "remedial" and "defensive" rather than monopolistic, these agreements were initially oriented only towards raising field prices in the aftermath of price wars. Combinations also allowed temporary alliances without requiring appreciable rationalisation, increased productivity, or expanded marketing. They also preserved individual autonomy and helped to maintain family control. Companies such as Whiffen and Howards were particularly deeply involved because of their traditional strengths in importing raw materials and relying on their shipping networks to supply markets. 4 Particularly good examples of these agreements are the caffeine, iodine, and camphor cartels. The first two were a result of the reaction of firms to the need for combinations and the third is an example of the fragility of these agreements owing to their inability to address the cause and not just the symptoms. These cartels were typical of arrangements used by German and British companies to try to stabilise trade, but they served the two national industries quite differently. To the Germans they opened markets overseas, and they took advantage of superior British supply routes. This facilitated their growth, especially by opening up new areas. For the British, however, the agreements were usually drawn up with the intention of covering products that were already being imported, processed, and sold or exported. Their advantage was primarily in fixing prices, and it was a defensive strategy that staved off competition. British interests were directed at Imperial territories-to postpone German commercial encroachment-and the United States-in the naive hope that they could regain their early nineteenth century position as major suppliers. What the British manufacturers failed to understand was that by emulating the German industry American manufacturers, with effective governmental aid, were being transformed fundamentally.4
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Foundations Th g fazbok fundamentally affected the drug manufacturers. The production of antibiotics was ordinarily more complex thani that of the biological drugs or even chemotherapeutic drugs, and hence even larger and more highly trained scientific staffs had to be assembled. Moreover, the subsequent search for other antibiotic drugs necessitated creative fundamental research and product development on a greater scale than ever before. Their proliferation was then matched by those ofthe psychoactive drugs ofthe 1950s. But none ofthis' was unprecedented. The company structure in which this took place, the laboratories and testing facilities, even the special relationships between marketing departments and doctors, had all been established in the years preceding the Great Depression.2 The thalidomide tragedy gave fuel to a range of opponents of drugs manufacturers, who objected to their high profits, their collusive behaviour, and their evidently inadequate checks on safety. A new relationship with the government was supposed to have emerged, but the real effect in the 1960s was to put the industry under stringent scrutiny over prices and to slow the process of drug approval by regulators. The 1960s saw the rise of the Japanese industry as part of the general boom in the Japanese economy and the broadening of the base for multinationalisation.8 9 
New scrutiny
The 1960s also saw the rise of a new scrutiny of the pharmaceutical industry. The Kefauver Committee in the United States Senate focused on the industry in their anti-monopoly investigations. After these investigations many discussions in the industry revolved around how to avoid abuses ofmonopoly type power while continuing to reward pharmaceutical companies for the financial risks that they took in developing new medicines that were beneficial to. society. In Britain there was a sharp response to the committee's findings, which was heightened by the impact of the thalidomide disaster. The Sainsbury Committee in 1967 considered the question of pharmaceutical pricing, and the Labour government toyed with the idea of nationalising the whole pharmaceutical industry.9-"
The size of the pharmaceuticals market has grown tremendously in recent years. The world market was estimated to be around $10 billion (unadjusted) in the mid-1960s. In the mid-1970s it was estimated at about $36 billion. By the early 1980s it was worth over $80 billion, most of it in sales to the developed market economies. The market is dominated by a small number of very large companies organised on a multinational basis and located in the United States, Germany, Switzerland, the United Kingdom, and Japan. There is continuing regulation over the introduction of new products in all of the largest countries, and most national governments regulate the prices that can be charged. The European market is divided along national and regional lines and accounts for just over a fifth of the world market. European production, however, accounts for more than a quarter of world output; it is concentrated in 33 firms, which have a capacity for serious product innovation. Additionally, there are about 1500 other manufacturers that produce primarily out of patent drugs or specialised products or work under licence.8-'0 Information, image, and reminder gifts Drug consumption varies internationally according to cultural and historical patterns. These differences have a great deal to do with attitudes towards therapeutics and towards the role ofdoctors and pharmacists. Other variations ofspecial importance follow economic and demographic trends. Drugs for treating the diseases of old age have come to dominate, as might be expected, in those countries with prosperous, generally healthy, but aging populations. 9 As for drug marketing, we have seen the evolution of an established manufacturing sector into a high technology industry and its adaptation of a scientific image that was most useful for marketing its products.
The question of the control of information about drugs continues to plague the medical world and its regulators. Recent studies in Britain and the United States have shed some light on the continuing role of manufacturers as sources of information. Company representatives still supply most information about the existence and cost of drugs, and whereas scholarly periodicals may be of greater influence and regarded as more reliable sources about the efficacy of new medicines, they are less accessible. " 12 Through the systematic use of trained representatives, the detail men, drug companies continue to maintain close personal contact with doctors. They frequently give doctors gifts and "reminder items." In the United States they gave away almost 200 small gifts to each doctor in 1973, just to establish a relationship and solidify the contact. Marketing and sociological studies have shown that doctors who see detail men tend to prescribe drugs from their companies after the visits. There seems to be a direct relation between the number of visits from a particular company and the propensity to prescribe a particular drug, and this closely matches the company's advertising expenses.8 '
From small scale businesses almost indistinguishable from patent medicine sellers the modern pharmaceutical industry has developed sophistication in marketing to match the complexity of the products.
While British companies grew more slowly than the American, Swiss, and German industries during the period after the first world war, in more recent times the leading manufacturers have become so international that the country where headquarters are located has become less important. With the increasing internationalisation of the industry techniques for using information about pharmaceutical products have tended to push manufacturers into an ever more important position in the medical community. At the turn ofthe century Paris was the cutural centre ofthe avant-garde and the natural aim ofany ambitious artist. Picasso arrivedfrom Barcelona in 1900, alternating between the two citiesfor the nextfour orfiveyears. This was a time when he was to suffer not onlypoverty but depression, which he translated into the works ofhis "blue," or classical, period. The themes ofthese pictures are usually poverty and despair, the subjects social outcasts.
One ofthe Spanish pictures ofthe blue period, the pastel "The Sick Child," is reminiscent ofa Madonna and Child. But there the likeness ends. It is a picture ofdespair. The boy's face is so emaciated that his cheekbones almost protrude through theflesh and it is painful to meet his eyes. Although his mother is touchingly protective, she cannot conceal her anguish. In less sensitive hands this theme might have been sentimental, but Picasso has produced a haunting image. In particular the subtle use ofblue over its entire range complements the subject and is an ideal symbol ofpoverty and sadness. Pastel is a notoriously difficult medium but Picasso uses it here with consummate skill. It 
